Cleveland BioLabs, Inc. (CBLI) stock is lower by 23.37% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CBLI Stock Today?
Cleveland BioLabs, Inc. (CBLI) stock has fallen -14.16% while the S&P 500 has gained 0.72% as of 3:32 PM on Monday, Aug 24. CBLI has fallen -$0.33 from the previous closing price of $2.33 on volume of 530,389 shares. Over the past year the S&P 500 is higher by 18.87% while CBLI has gained 38.89%. CBLI lost -$0.19 per share in the over the last 12 months.
To see the top 5 stocks in the Biotechnology industry click here.
More About Cleveland BioLabs, Inc.
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
